Chemotherapy-induced constipation and diarrhea: Pathophysiology, current and emerging treatments

Frontiers in Pharmacology

Volumn 7, Issue NOV, 2016, Pages

  McQuade, Rachel M ^a   Stojanovska, Vanesa ^a   Abalo, Raquel ^b,c,d   Bornstein, Joel C ^e   Nurgali, Kulmira ^a  

^a VICTORIA UNIVERSITY   (Australia)

^b UNIVERSIDAD REY JUAN CARLOS   (Spain)

^c CSIC   (Spain)

^d INSTITUTE OF FOOD SCIENCE RESEARCH CIAL   (Spain)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Chemotherapy; Chemotherapy induced constipation; Chemotherapy induced diarrhea; Pathophy siology; Treatments

Indexed keywords

17 METHYLNALTREXONE; ALVIMOPAN; BISACODYL; CABAZITAXEL; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; DRONABINOL; FIRTECAN; FIRTECAN GLUCURONIDE; FLUOROURACIL; GEMCITABINE; IRINOTECAN; LAXATIVE; LINACLOTIDE; LIQUID PARAFFIN; LOPERAMIDE; LUBIPROSTONE; METHOTREXATE; NARCOTIC ANALGESIC AGENT; OCTREOTIDE; OPIATE; OXALIPLATIN; PACLITAXEL; TARANABANT; THALIDOMIDE; UNINDEXED DRUG; VINCRISTINE;

APOPTOSIS; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED CONSTIPATION; CHEMOTHERAPY INDUCED DIARRHEA; CONSTIPATION; CRYPT CELL; DIARRHEA; DISEASE CLASSIFICATION; DISEASE SEVERITY; ELECTROLYTE BALANCE; EXERCISE; FECES IMPACTION; FLUID INTAKE; GASTROINTESTINAL TRANSIT; HOMEOSTASIS; HUMAN; INTESTINE FLORA; INTESTINE INNERVATION; MUCOSA INFLAMMATION; MYENTERIC PLEXUS; NONHUMAN; OPIOID INDUCED CONSTIPATION; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STOMACH MUCOSA LESION; SUBMUCOUS PLEXUS; TINCTURE;

EID: 85003749673     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2016.00414     Document Type: Review

References (183)

1. Abalo, R., Chen, C., Vera, G., Fichna, J., Thakur, G., López-Pérez, A., et al. (2015). In vitro and non-invasive in vivo effects of the cannabinoid-1 receptor agonist AM841 on gastrointestinal motor function in the rat. Neurogastroenterol. Motil. 27, 1721-1735. doi: 10.1111/nmo.12668
2. Abalo, R., Uranga, J. A., Pérez-García, I., De Andrés, R., Girón, R., Vera, G., et al. (2016). May cannabinoids prevent the development of chemotherapy-induced diarrhea and intestinal mucositis? Experimental study in the rat. Neurogastroenterol. Motil. doi: 10.1111/nmo.12952 [Epub ahead of print]
3. Abalo, R., Vera, G., López-Pérez, A. E., Martínez-Villaluenga, M., and Martín-Fontelles, M. I. (2012). The gastrointestinal pharmacology of cannabinoids: focus on motility. Pharmacology 90, 1-10. doi: 10.1159/000339072
4. Abernethy, A. P., Wheeler, J. L., and Zafar, S. Y. (2009). Detailing of gastrointestinal symptoms in cancer patients with advanced disease: new methodologies, new insights, and a proposed approach. Curr. Opin. Support. Palliat. Care 3, 41-49. doi: 10.1097/SPC.0b013e32832531ce
5. Abramowitz, L., Béziaud, N., Labreze, L., Giardina, V., Caussé, C., Chuberre, B., et al. (2013). Prevalence and impact of constipation and bowel dysfunction induced by strong opioids: a cross-sectional survey of 520 patients with cancer pain: DYONISOS study. J. Med. Econ. 16, 1423-1433. doi: 10.3111/13696998.2013.851082
6. Andresen, V., Camilleri, M., Busciglio, I. A., Grudell, A., Burton, D., Mckinzie, S., et al. (2007). Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology 133, 761-768. doi: 10.1053/j.gastro.2007.06.067
7. Anthony, L. B. (2010). "Diarrhea, constipation, and obstruction in cancer management, " in The MASCC Textbook of Cancer Supportive Care and Survivorship, ed. N. Ian Olver (Berlin: Springer), 249-260.
8. Araki, E., Ishikawa, M., Iigo, M., Koide, T., Itabashi, M., and Hoshi, A. (1993). Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Cancer Sci. 84, 697-702.
9. Arbuckle, R., Huber, S., and Zacker, C. (2000). The consequences of diarrhea occurring during chemotherapy for colorectal cancer: a retrospective study. Oncologist 5, 250-259. doi: 10.1634/theoncologist.5-3-250
10. Ardizzoni, A., Boni, L., Tiseo, M., Fossella, F. V., Schiller, J. H., Paesmans, M., et al. (2007). Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J. Natl. Cancer Inst. 99, 847-857. doi: 10.1093/jnci/djk196
11. Ashraf, W., Park, F., Lof, J., and Quigley, E. M. (1996). An examination of the reliability of reported stool frequency in the diagnosis of idiopathic constipation. Am. J. Gastroenterol. 91, 26-32.
12. Avila, J. G. (2004). Pharmacologic treatment of constipation in cancer patients. Cancer Control 11, 10-18.
13. Bassotti, G., and Villanacci, V. (2011). Can "functional" constipation be considered as a form of enteric neuro-gliopathy? Glia 59, 345-350. doi: 10.1002/glia.21115
14. Benson, A. B., Ajani, J. A., Catalano, R. B., Engelking, C., Kornblau, S. M., Martenson, J. A., et al. (2004a). Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J. Clin. Oncol. 22, 2918-2926. doi: 10.1200/JCO.2004.04.132
15. Benson, A. B., Schrag, D., Somerfield, M. R., Cohen, A. M., Figueredo, A. T., Flynn, P. J., et al. (2004b). American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J. Clin. Oncol. 22, 3408-3419. doi: 10.1200/JCO.2004.05.063
16. Benyamin, R., Trescot, A. M., Datta, S., Buenaventura, R., Adlaka, R., Sehgal, N., et al. (2008). Opioid complications and side effects. Pain Physician 11, S105-S120.
17. Bhattacharya, S., Vijayasekar, C., Worlding, J., and Mathew, G. (2008). Octreotide in chemotherapy induced diarrhoea in colorectal cancer: a review article. Acta Gastroenterol. Belg. 72, 289-295.
18. Bijvelds, M. J., Bot, A. G., Escher, J. C., and De Jonge, H. R. (2009). Activation of intestinal Cl-secretion by lubiprostone requires the cystic fibrosis transmembrane conductance regulator. Gastroenterology 137, 976-985. doi: 10.1053/j.gastro.2009.05.037
19. Boussios, S., Pentheroudakis, G., Katsanos, K., and Pavlidis, N. (2012). Systemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and management. Ann. Gastroenterol. 25, 106-118.
20. Bowen, J. M., Stringer, A. M., Gibson, R. J., Yeoh, A. S., Hannam, S., and Keefe, D. M. (2007). VSL# 3 probiotic treatment reduces chemotherapy-induced diarrhoea and weight loss. Cancer Biol. Ther. 6, 1445-1450. doi: 10.4161/cbt.6.9.4622
21. Bültzingslöwen, I., Adlerberth, I., Wold, A., Dahlén, G., and Jontell, M. (2003). Oral and intestinal microflora in 5-fluorouracil treated rats, translocation to cervical and mesenteric lymph nodes and effects of probiotic bacteria. Oral Microbiol. Immunol. 18, 278-284. doi: 10.1034/j.1399-302X.2003.00075.x
22. Camilleri, M. (2010). Review article: new receptor targets for medical therapy in irritable bowel syndrome. Aliment. Pharmacol. Ther. 31, 35-46. doi: 10.1111/j.1365-2036.2009.04153.x
23. Camilleri, M. (2011). Opioid-induced constipation: challenges and therapeutic opportunities. Am. J. Gastroenterol. 106, 835-842. doi: 10.1038/ajg.2011.30
24. Camilleri, M., Bharucha, A. E., Ueno, R., Burton, D., Thomforde, G. M., Baxter, K., et al. (2006). Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am. J. Physiol.Gastrointest. Liver Physiol. 290, G942-G947. doi: 10.1152/ajpgi.00264.2005
25. Carelle, N., Piotto, E., Bellanger, A., Germanaud, J., Thuillier, A., and Khayat, D. (2002). Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 95, 155-163. doi: 10.1002/cncr.10630
26. Castro-Rodríguez, J. A., Salazar-Lindo, E., and León-Barúa, R. (1997). Differentiation of osmotic and secretory diarrhoea by stool carbohydrate and osmolar gap measurements. Arch. Dis. Child. 77, 201-205. doi: 10.1136/adc.77.3.201
27. Chandrasekharan, B., Anitha, M., Blatt, R., Shahnavaz, N., Kooby, D., Staley, C., et al. (2011). Colonic motor dysfunction in human diabetes is associated with enteric neuronal loss and increased oxidative stress. Neurogastroenterol. Motil. 23, 131-138. doi: 10.1111/j.1365-2982.2010.01611.x
28. Connolly, M., and Larkin, P. (2012). Managing constipation: a focus on care and treatment in the palliative setting. Br. J. Community Nurs. 17, 60-67. doi: 10.12968/bjcn.2012.17.2.60
29. Cortesini, C., Cianchi, F., Infantino, A., and Lise, M. (1995). Nitric oxide synthase and VIP distribution in enteric nervous system in idiopathic chronic constipation. Dig. Dis. Sci. 40, 2450-2455. doi: 10.1007/BF02063253
30. Costilla, V. C., and Foxx-Orenstein, A. E. (2014). Constipation: understanding mechanisms and management. Clin. Geriatr. Med. 30, 107-115. doi: 10.1016/j.cger.2013.10.001
31. Culpepper-Morgan, J. A., Inturrisi, C. E., Portenoy, R. K., Foley, K., Houde, R. W., Marsh, F., et al. (1992). Treatment of opioid-induced constipation with oral naloxone: a pilot study. Clin. Pharmacol. Ther. 52, 90-95. doi: 10.1038/clpt.1992.106
32. Davis, M., and Gamier, P. (2015). New options in constipation management. Curr. Oncol. Rep. 17, 1-11. doi: 10.1007/s11912-015-0481-x
33. De Giorgio, R., and Camilleri, M. (2004). Human enteric neuropathies: morphology and molecular pathology. Neurogastroenterol. Motil. 16, 515-531. doi: 10.1111/j.1365-2982.2004.00538.x
34. De Giorgio, R., Guerrini, S., Barbara, G., Cremon, C., Stanghellini, V., and Corinaldesi, R. (2004). New insights into human enteric neuropathies. Neurogastroenterol. Motil. 16, 143-147. doi: 10.1111/j.1743-3150.2004.00491.x
35. De Giorgio, R., Stanghellini, V., Barbara, G., Corinaldesi, R., De Ponti, F., Tonini, M., et al. (2000). Primary enteric neuropathies underlying gastrointestinal motor dysfunction. Scand. J. Gastroenterol. 35, 114-122. doi: 10.1080/003655200750024263
36. Denlinger, C. S., and Barsevick, A. M. (2009). The challenges of colorectal cancer survivorship. J. Natl. Compr. Canc. Netw. 7, 883-894.
37. Dennison, C., Prasad, M., Lloyd, A., Bhattacharyya, S. K., Dhawan, R., and Coyne, K. (2005). The health-related quality of life and economic burden of constipation. Pharmacoeconomics 23, 461-476. doi: 10.2165/00019053-200523050-00006
38. De Schepper, H. U., Cremonini, F., Park, M. I., and Camilleri, M. (2004). Opioids and the gut: pharmacology and current clinical experience. Neurogastroenterol. Motil. 16, 383-394. doi: 10.1111/j.1365-2982.2004.00513.x
39. Dieras, V., Lortholary, A., Laurence, V., Delva, R., Girre, V., Livartowski, A., et al. (2013). Cabazitaxel in patients with advanced solid tumours: results of a phase I and pharmacokinetic study. Eur. J. Cancer 49, 25-34. doi: 10.1016/j.ejca.2012.07.008
40. Dinning, P., Smith, T., and Scott, S. (2009). Pathophysiology of colonic causes of chronic constipation. Neurogastroenterol. Motil. 21, 20-30. doi: 10.3748/wjg.v19.i26.4099
41. Dosh, S. A. (2002). Evaluation and treatment of constipation (Clinical Update). J. Fam. Pract. 51, 555-560.
42. Douillard, J.-Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., et al. (2010). Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J. Clin. Oncol. 28, 4697-4705. doi: 10.1200/JCO.2009.27.4860
43. Dranitsaris, G., Maroun, J., and Shah, A. (2005). Estimating the cost of illness in colorectal cancer patients who were hospitalized for severe chemotherapy-induced diarrhea. Can. J. Gastroenterol. 19, 83-87. doi: 10.1155/2005/618504
44. Esfandyari, T., Camilleri, M., Busciglio, I., Burton, D., Baxter, K., and Zinsmeister, A. R. (2007). Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study. Am. J. Physiol. Gastrointest. Liver Physiol. 293, G137-G145. doi: 10.1152/ajpgi.00565.2006
45. Esfandyari, T., Camilleri, M., Ferber, I., Burton, D., Baxter, K., and Zinsmeister, A. (2006). Effect of a cannabinoid agonist on gastrointestinal transit and postprandial satiation in healthy human subjects: a randomized, placebo-controlled study. Neurogastroenterol. Motil. 18, 831-838. doi: 10.1111/j.1365-2982.2006.00834.x
46. Extra, J. M., Espie, M., Calvo, F., Ferme, C., Mignot, L., and Marty, M. (1990). Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother. Pharmacol. 25, 299-303. doi: 10.1007/BF00684890
47. Falcón, B. S., López, M. B., Muñoz, B. M., Sánchez, A. á, and Rey, E. (2016). Fecal impaction: a systematic review of its medical complications. BMC Geriatrics 16:4. doi: 10.1186/s12877-015-0162-5
48. Fallon, M., and O'Neill, B. (1997). ABC of palliative care. Constipation and diarrhoea. BMJ: Br. Med. J. 315, 1293-1296. doi: 10.1136/bmj.315.7118.1293
49. Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., et al. (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359-E386. doi: 10.1002/ijc.29210
50. Fichna, J., Sibaev, A., Salaga, M., Sobczak, M., and Storr, M. (2013). The cannabinoid-1 receptor inverse agonist taranabant reduces abdominal pain and increases intestinal transit in mice. Neurogastroenterol. Motil. 25, e550-e559. doi: 10.1111/nmo.12158
51. Fickel, J., Bagnol, D., Watson, S. J., and Akil, H. (1997). Opioid receptor expression in the rat gastrointestinal tract: a quantitative study with comparison to the brain. Brain Res. Mol. Brain Res. 46, 1-8. doi: 10.1016/S0169-328X(96)00266-5
52. Fittkau, M., Voigt, W., Holzhausen, H.-J., and Schmoll, H.-J. (2004). Saccharic acid 1.4-lactone protects against CPT-11-induced mucosa damage in rats. J. Cancer Res. Clin. Oncol. 130, 388-394. doi: 10.1007/s00432-004-0557-8
53. Ford, A. C., and Suares, N. C. (2011). Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis. Gut 60, 209-218. doi: 10.1136/gut.2010.227132
54. Fox, D. A., Epstein, M. L., and Bass, P. (1983). Surfactants selectively ablate enteric neurons of the rat jejunum. J. Pharmacol. Exp. Ther. 227, 538-544.
55. Fraiser, L. H., Kanekal, S., and Kehrer, J. P. (1991). Cyclophosphamide toxicity. Drugs 42, 781-795. doi: 10.2165/00003495-199142050-00005
56. Furness, J. B. (2012). The enteric nervous system and neurogastroenterology. Nat. Rev. Gastroenterol. Hepatol. 9, 286-294. doi: 10.1038/nrgastro.2012.32
57. Garg, S., Nurgali, K., and Mishra, V. K. (2016). Food proteins as source of opioid peptides-a review. Curr. Med. Chem. 23, 893-910. doi: 10.2174/0929867323666160219115226
58. Gatti, A., and Sabato, A. F. (2012). Management of opioid-induced constipation in cancer patients. Clin. Drug Investig. 32, 293-301. doi: 10.2165/11598000-000000000-00000
59. Ghobrial, I. M., and Rajkumar, V. S. (2003). Management of thalidomide toxicity. J. Support. Oncol. 1, 194-213.
60. Gibson, R. J., Bowen, J. M., Inglis, M. R., Cummins, A. G., and Keefe, D. M. (2003). Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J. Gastroenterol. Hepatol. 18, 1095-1100. doi: 10.1046/j.1440-1746.2003.03136.x
61. Gibson, R. J., and Keefe, D. M. (2006). Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies. Support. Care Cancer 14, 890-900. doi: 10.1007/s00520-006-0040-y
62. Goffin, J., Lacchetti, C., Ellis, P. M., Ung, Y. C., and Evans, W. K. (2010). First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review. J. Thorac. Oncol. 5, 260-274. doi: 10.1097/JTO.0b013e3181c6f035
63. Gonzalez, C. E., and Halm, J. K. (2016). "Constipation in cancer patients, " in Oncologic Emergency Medicine, eds K. H. Todd, C. R. Jr. Thomas (Switzerland: Springer International Publishing), 327-332. doi: 10.1007/978-3-319-26387-8_28
64. Gwynne, R. M., Thomas, E., Goh, S., Sjövall, H., and Bornstein, J. (2004). Segmentation induced by intraluminal fatty acid in isolated guinea-pig duodenum and jejunum. J. Physiol. 556, 557-569. doi: 10.1113/jphysiol.2003.057182
65. Hansen, M. B. (2003). The enteric nervous system II: gastrointestinal functions. Pharmacol. Toxicol. 92, 249-257. doi: 10.1034/j.1600-0773.2003.920601.x
66. Harris, L. A., and Crowell, M. D. (2007). Linaclotide, a new direction in the treatment of irritable bowel syndrome and chronic constipation. Curr. Opin. Mol. Ther. 9, 403-410.
67. He, C. L., Burgart, L., Wang, L., Pemberton, J., Young-Fadok, T., Szurszewski, J., et al. (2000). Decreased interstitial cell of Cajal volume in patients with slow-transit constipation. Gastroenterology 118, 14-21. doi: 10.1016/S0016-5085(00)70409-4
68. Hecht, J. R. (1998). Gastrointestinal toxicity or irinotecan. Oncology (Williston Park) 12, 72-78.
69. Hinds, N. M., Ullrich, K., and Smid, S. D. (2006). Cannabinoid 1 (CB1) receptors coupled to cholinergic motorneurones inhibit neurogenic circular muscle contractility in the human colon. Br. J. Pharmacol. 148, 191-199. doi: 10.1038/sj.bjp.0706710
70. Högenauer, C., Aichbichler, B., Santa Ana, C., Porter, J., and Fordtran, J. (2002). Effect of octreotide on fluid absorption and secretion by the normal human jejunum and ileum in vivo. Aliment. Pharmacol. Ther. 16, 769-777. doi: 10.1046/j.1365-2036.2002.01228.x
71. Holland, J. F., Scharlau, C., Gailani, S., Krant, M. J., Olson, K. B., Horton, J., et al. (1973). Vincristine treatment of advanced cancer: a cooperative study of 392 cases. Cancer Res. 33, 1258-1264.
72. Huizinga, J. D., and Lammers, W. J. (2009). Gut peristalsis is governed by a multitude of cooperating mechanisms. Am. J. Physiol.Gastrointest. Liver Physiol. 296, G1-G8. doi: 10.1152/ajpgi.90380.2008
73. Ikuno, N., Soda, H., Watanabe, M., and Oka, M. (1995). Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum. J. Natl. Cancer Inst. 87, 1876-1883. doi: 10.1093/jnci/87.24.1876
74. Ilson, D. H., Saltz, L., Enzinger, P., Huang, Y., Kornblith, A., Gollub, M., et al. (1999). Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J. Clin. Oncol. 17, 3270-3275.
75. Iwamoto, T. (2013). Clinical application of drug delivery systems in cancer chemotherapy: review of the efficacy and side effects of approved drugs. Biol. Pharm. Bull. 36, 715-718. doi: 10.1248/bpb.b12-01102
76. Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., and Forman, D. (2011). Global cancer statistics. CA Cancer J. Clin. 61, 69-90. doi: 10.3322/caac.20107
77. Jemal, A., Center, M. M., Desantis, C., and Ward, E. M. (2010a). Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol. Biomarkers Prev. 19, 1893-1907. doi: 10.1158/1055-9965.EPI-10-0437
78. Jemal, A., Siegel, R., Xu, J., and Ward, E. (2010b). Cancer statistics, 2010. CA Cancer J. Clin. 60, 277-300. doi: 10.3322/caac.20073
79. Johnson, L., Ghishan, F. K., Kaunitz, J., Merchant, J., Said, H., and Wood, J. (2012). Physiology of the Gastrointestinal Tract. Amsterdam: Elsevier Inc.
80. Johnston, J. M., Kurtz, C. B., Drossman, D. A., Lembo, A. J., Jeglinski, B. I., Macdougall, J. E., et al. (2009). Pilot study on the effect of linaclotide in patients with chronic constipation. Am. J. Gastroenterol. 104, 125-132. doi: 10.1038/ajg.2008.59
81. Johnston, J. M., Kurtz, C. B., Macdougall, J. E., Lavins, B. J., Currie, M. G., Fitch, D. A., et al. (2010). Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology 139, 1877-1886. doi: 10.1053/j.gastro.2010.08.041
82. Jun, J. Y. (2013). Role of lubiprostone on gastrointestinal motility. J Neurogastroenterol. Motil. 19, 277-278. doi: 10.5056/jnm.2013.19.3.277
83. Kase, Y., Hayakawa, T., Aburada, M., Komatsu, Y., and Kamataki, T. (1997a). Preventive effects of Hange-shashin-to on irinotecan hydrochloride-caused diarrhea and its relevance to the colonic prostaglandin E2 and water absorption in the rat. Jpn. J. Pharmacol. 75, 407-413. doi: 10.1254/jjp.75.407
84. Kase, Y., Hayakawa, T., Togashi, Y., and Kamataki, T. (1997b). Relevance of irinotecan hydrochloride-induced diarrhea to the level of prostaglandin E2 and water absorption of large intestine in rats. Jpn. J. Pharmacol. 75, 399-405. doi: 10.1254/jjp.75.407
85. Kaufmann, M., Hortobagyi, G. N., Goldhirsch, A., Scholl, S., Makris, A., Valagussa, P., et al. (2006). Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J. Clin. Oncol. 24, 1940-1949. doi: 10.1200/JCO.2005.02.6187
86. Keefe, D., Brealey, J., Goland, G., and Cummins, A. (2000). Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut 47, 632-637. doi: 10.1136/gut.47.5.632
87. Kim, A. R., Cho, J., Hsu, Y.-J., Choi, M. G., Noh, J. H., Sohn, T. S., et al. (2012). Changes of quality of life in gastric cancer patients after curative resection: a longitudinal cohort study in Korea. Ann. Surg. 256, 1008-1013. doi: 10.1097/SLA.0b013e31827661c9
88. Kim, D., Kim, J., Lee, S.-H., Kim, T., Heo, D., Bang, Y.-J., et al. (2003). Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer. Ann. Oncol. 14, 383-387. doi: 10.1093/annonc/mdg106
89. Kirschenbaum, H. L. (2001). Handbook of nonprescription drugs. Am. J. Pharm. Educ. 65, 100.
90. Klaschik, E., Nauck, F., and Ostgathe, C. (2003). Constipation-modern laxative therapy. Support. Care Cancer 11, 679-685. doi: 10.1007/s00520-003-0525-x
91. Ko, E.-A., Jin, B.-J., Namkung, W., Ma, T., Thiagarajah, J. R., and Verkman, A. (2014). Chloride channel inhibition by a red wine extract and a synthetic small molecule prevents rotaviral secretory diarrhoea in neonatal mice. Gut 63, 1120-1129. doi: 10.1136/gutjnl-2013-305663
92. Kuebler, P. J., Colangelo, L., O'connell, M. J., Smith, R. E., Yothers, G., Begovic, M., et al. (2007). Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin. Cancer 110, 1945-1950. doi: 10.1002/cncr.23013
93. Kuizenga, M. H., Sia, T. C., Dodds, K. N., Wiklendt, L., Arkwright, J. W., Thomas, A., et al. (2015). Neurally mediated propagating discrete clustered contractions superimposed on myogenic ripples in ex vivo segments of human ileum. American Journal of Physiology-Gastrointestinal and Liver Physiology 308, G1-G11. doi: 10.1152/ajpgi.00230.2014
94. Kurniawan, I., and Simadibrata, M. (2011). Management of chronic constipation in the elderly. Acta Med Indones 43, 195-205.
95. Lacy, B. E., and Levy, L. C. (2007). Lubiprostone: a chloride channel activator. J. Clin. Gastroenterol. 41, 345-351. doi: 10.1097/01.mcg.0000225665.68920.df
96. Lawrence, T. (2009). The nuclear factor NF-κB pathway in inflammation. Cold Spring Harb. Perspect. Biol. 1, a001651. doi: 10.1101/cshperspect.a001651
97. Leahy, K. M., Ornberg, R. L., Wang, Y., Zweifel, B. S., Koki, A. T., and Masferrer, J. L. (2002). Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res. 62, 625-631.
98. Lee, C. S., Ryan, E. J., and Doherty, G. A. (2014). Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation. World J. Gastroenterol. 20, 3751-3761. doi: 10.3748/wjg.v20.i14.3751
99. Lembo, A., and Camilleri, M. (2003). Chronic constipation. N. Engl. J. Med. 349, 1360-1368. doi: 10.1056/NEJMra020995
100. Lembo, A. J., Kurtz, C. B., Macdougall, J. E., Lavins, B., Currie, M. G., Fitch, D. A., et al. (2010). Efficacy of linaclotide for patients with chronic constipation. Gastroenterology 138, 886-895. doi: 10.1053/j.gastro.2009.12.050
101. Lenfers, B., Loeffer, T., Droege, C., and Hausamen, T. (1999). Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment. Ann. Oncol. 10, 1251-1253. doi: 10.1023/A:1008390308416
102. Leung, L., Riutta, T., Kotecha, J., and Rosser, W. (2011). Chronic constipation: an evidence-based review. J. Am. Board Fam. Med. 24, 436-451. doi: 10.3122/jabfm.2011.04.100272
103. Loening-Baucke, V. (1996). Encopresis and soiling. Pediatr. Clin. North Am. 43, 279-298. doi: 10.1016/S0031-3955(05)70406-5
104. Logan, R. M., Gibson, R. J., Bowen, J. M., Stringer, A. M., Sonis, S. T., and Keefe, D. M. (2008). Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother. Pharmacol. 62, 33-41. doi: 10.1007/s00280-007-0570-0
105. Louvet, C., Andre, T., Tigaud, J., Gamelin, E., Douillard, J., Brunet, R., et al. (2002). Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J. Clin. Oncol. 20, 4543-4548. doi: 10.1200/JCO.2002.02.021
106. Lundgren, O., Peregrin, A. T., Persson, K., Kordasti, S., Uhnoo, I., and Svensson, L. (2000). Role of the enteric nervous system in the fluid and electrolyte secretion of rotavirus diarrhea. Science 287, 491-495. doi: 10.1126/science.287.5452.491
107. MacDonald, A., Shearer, M., Paterson, P., and Finlay, I. (1991). Relationship between outlet obstruction constipation and obstructed urinary flow. Br. J. Surg. 78, 693-695. doi: 10.1002/bjs.1800780620
108. Mancini, I., and Bruera, E. (1998). Constipation in advanced cancer patients. Support. Care Cancer 6, 356-364. doi: 10.1007/s005200050177
109. Maroun, J. A., Anthony, L. B., Blais, N., Burkes, R., Dowden, S. D., Dranitsaris, G., et al. (2007). Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the canadian working group on chemotherapy-induced diarrhea. Curr. Oncol. 14, 13-20. doi: 10.3747/co.2007.96
110. Matsuda, C., Munemoto, Y., Mishima, H., Nagata, N., Oshiro, M., Kataoka, M., et al. (2015). Double-blind, placebo-controlled, randomized phase II study of TJ-14 (Hangeshashinto) for infusional fluorinated-pyrimidine-based colorectal cancer chemotherapy-induced oral mucositis. Cancer Chemother. Pharmacol. 76, 97-103. doi: 10.1007/s00280-015-2767-y
111. McKay, J. S., Linaker, B. D., and Turnberg, L. A. (1981). Influence of opiates on ion transport across rabbit ileal mucosa. Gastroenterology 80, 279-284.
112. McQuade, R., Stojanovska, V., Donald, E., Abalo, R., Bornstein, J., and Nurgali, K. (2016). Gastrointestinal dysfunction and enteric neurotoxicity following treatment with anticancer chemotherapeutic agent 5-fluorouracil. Neurogastroenterol. Motil. doi: 10.1111/nmo.12890 [Epub ahead of print]
113. McQuade, R. M., Bornstein, J. C., and Nurgali, K. (2014). Anti-colorectal cancer chemotherapy-induced diarrhoea: current treatments and side-effects. Int. J. Clin. Med. 5, 393-406. doi: 10.4236/ijcm.2014.57054
114. Mitchell, E. P. (2006). Gastrointestinal toxicity of chemotherapeutic agents. Semin. Oncol. 33, 106-120. doi: 10.1053/j.seminoncol.2005.12.001
115. Mori, K., Kondo, T., Kamiyama, Y., Kano, Y., and Tominaga, K. (2003). Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer. Cancer Chemother. Pharmacol. 51, 403-406.
116. Mutch, D. G., Orlando, M., Goss, T., Teneriello, M. G., Gordon, A. N., Mcmeekin, S. D., et al. (2007). Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J. Clin. Oncol. 25, 2811-2818. doi: 10.1200/JCO.2006.09.6735
117. Nightingale, G., and Ryu, J. (2012). Cabazitaxel (jevtana): a novel agent for metastatic castration-resistant prostate cancer. Pharm. Ther. 37, 440-448.
118. Okines, A., Verheij, M., Allum, W., Cunningham, D., Cervantes, A., and Group, E. G. W. (2010). Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21, v50-v54. doi: 10.1093/annonc/mdq164
119. O'Mahony, S., Coyle, N., and Payne, R. (2001). Current management of opioid-related side effects. Oncology (Williston Park) 15, 61-82.
120. Österlund, P., Ruotsalainen, T., Korpela, R., Saxelin, M., Ollus, A., Valta, P., et al. (2007). Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. Br. J. Cancer 97, 1028-1034. doi: 10.1038/sj.bjc.6603990
121. Panchal, S. J., Müller-Schwefe, P., and Wurzelmann, J. I. (2007). Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int. J. Clin. Pract. 61, 1181-1187. doi: 10.1111/j.1742-1241.2007.01415.x
122. Peterson, D., Bensadoun, R.-J., Roila, F., and Group, E. G. W. (2011). Management of oral and gastrointestinal mucositis: ESMO clinical practice guidelines. Ann. Oncol. 22, vi78-vi84. doi: 10.1093/annonc/mdr391
123. Phillips, R. J., and Powley, T. L. (2007). Innervation of the gastrointestinal tract: patterns of aging. Auton. Neurosci. 136, 1-19. doi: 10.1016/j.autneu.2007.04.005
124. Pini, A., Garella, R., Idrizaj, E., Calosi, L., Baccari, M., and Vannucchi, M. (2016). Glucagon-like peptide 2 counteracts the mucosal damage and the neuropathy induced by chronic treatment with cisplatin in the mouse gastric fundus. Neurogastroenterol. Motil. 28, 206-216. doi: 10.1111/nmo.12712
125. Pinto, L., Izzo, A. A., Mascolo, N., Capasso, F., Cascio, M. G., Bisogno, T., et al. (2002). Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology 123, 227-234. doi: 10.1053/gast.2002.34242
126. Pujol, J. L., Viens, P., Rebattu, P., Laurie, S. A., Feld, R., Deneulin, A., et al. (2006). Gefitinib (IRESSA) with vinorelbine or vinorelbine/cisplatin for chemotherapy-naive non-small cell lung cancer patients. J. Thorac. Oncol. 1, 417-424. doi: 10.1097/01243894-200606000-00007
127. Regnard, C., Twycross, R., Mihalyo, M., and Wilcock, A. (2011). Loperamide. J. Pain Symptom Manage. 42, 319-323. doi: 10.1016/j.jpainsymman.2011.06.001
128. Richardson, G., and Dobish, R. (2007). Chemotherapy induced diarrhea. J. Oncol. Pharm. Pract. 13, 181-198. doi: 10.1177/1078155207077335
129. Robinson, A. M., Stojanovska, V., Rahman, A. A., McQuade, R. M., Senior, P. V., and Nurgali, K. (2016). Effects of oxaliplatin treatment on the enteric glial cells and neurons in the mouse ileum. J. Histochem. Cytochem. 64, 530-545. doi: 10.1369/0022155416656842
130. Rothenberg, M. L., Meropol, N. J., Poplin, E. A., Van Cutsem, E., and Wadler, S. (2001). Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J. Clin. Oncol. 19, 3801-3807.
131. Rubenstein, E. B., Peterson, D. E., Schubert, M., Keefe, D., Mcguire, D., Epstein, J., et al. (2004). Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100, 2026-2046. doi: 10.1002/cncr.20163
132. Ruston, T., Hunter, K., Cummings, G., and Lazarescu, A. (2013). Efficacy and side-effect profiles of lactulose, docusate sodium, and sennosides compared to PEG in opioid-induced constipation: a systematic review. Can. Oncol. Nurs. J. 23, 236-240. doi: 10.5737/1181912x234236240
133. Sakai, H., Sato, T., Hamada, N., Yasue, M., Ikari, A., Kakinoki, B., et al. (1997). Thromboxane A2, released by the anti-tumour drug irinotecan, is a novel stimulator of Cl-secretion in isolated rat colon. J. Physiol. 505, 133-144. doi: 10.1111/j.1469-7793.1997.133bc.x
134. Scarlett, Y. (2004). Medical management of fecal incontinence. Gastroenterology 126, S55-S63. doi: 10.1053/j.gastro.2003.10.007
135. Schey, R., and Rao, S. S. (2011). Lubiprostone for the treatment of adults with constipation and irritable bowel syndrome. Dig. Dis. Sci. 56, 1619-1625. doi: 10.1007/s10620-011-1702-2
136. Schiller, L. R. (1999). Clinical pharmacology and use of laxatives and lavage solutions. J. Clin. Gastroenterol. 28, 11-18. doi: 10.1097/00004836-199901000-00003
137. Schneider, E. C., Malin, J. L., Kahn, K. L., Ko, C. Y., Adams, J., and Epstein, A. M. (2007). Surviving colorectal cancer. Cancer 110, 2075-2082. doi: 10.1002/cncr.23021
138. Shafi, M. A., and Bresalier, R. S. (2010). The gastrointestinal complications of oncologic therapy. Gastroenterol. Clin. North Am. 39, 629-647. doi: 10.1016/j.gtc.2010.08.004
139. Sharma, R., Tobin, P., and Clarke, S. J. (2005). Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. Lancet Oncol. 6, 93-102. doi: 10.1016/S1470-2045(05)01735-3
140. Smith, L. C., Bertolotti, P., Curran, K., and Jenkins, B. (2008). Gastrointestinal side effects associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF nurse leadership board. Clin. J. Oncol. Nurs. 12, 37-52. doi: 10.1188/08.CJON.S1.37-51
141. Sonis, S. T., Elting, L. S., Keefe, D., Peterson, D. E., Schubert, M., Hauer-Jensen, M., et al. (2004). Perspectives on cancer therapy-induced mucosal injury. Cancer 100, 1995-2025. doi: 10.1002/cncr.20162
142. Stathopoulos, G., Koutantos, J., Lazaki, H., Rigatos, S., Stathopoulos, J., and Deliconstantinos, G. (2007). Capecitabine (Xeloda) as monotherapy in advanced breast and colorectal cancer: effectiveness and side-effects. Anticancer Res. 27, 1653-1656.
143. Stein, A., Voigt, W., and Jordan, K. (2010). Review: chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv. Med. Oncol. 2, 51-63. doi: 10.1177/1758834009355164
144. Stojanovska, V., Sakkal, S., and Nurgali, K. (2015). Platinum-based chemotherapy: gastrointestinal immunomodulation and enteric nervous system toxicity. Am. J. Physiol.Gastrointest. Liver Physiol. 308, G223-G232. doi: 10.1152/ajpgi.00212.2014
145. Stringer, A. M. (2009). Chemotherapy-induced mucositis: the role of gastrointestinal microflora and mucins in the luminal environment. J. Support Oncol. 5, 259-267.
146. Stringer, A. M. (2013). Interaction between host cells and microbes in chemotherapy-induced mucositis. Nutrients 5, 1488-1499. doi: 10.3390/nu5051488
147. Stringer, A. M., Gibson, R. J., Bowen, J. M., and Keefe, D. M. (2009a). Chemotherapy-induced modifications to gastrointestinal microflora: evidence and implications of change. Curr. Drug Metab. 10, 79-83. doi: 10.2174/138920009787048419
148. Stringer, A. M., Gibson, R. J., Bowen, J. M., Logan, R. M., Ashton, K., Yeoh, A. S., et al. (2009b). Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile. Int. J. Exp. Pathol. 90, 489-499. doi: 10.1111/j.1365-2613.2009.00671.x
149. Stringer, A. M., Gibson, R. J., Logan, R. M., Bowen, J. M., Yeoh, A. S., Hamilton, J., et al. (2009c). Gastrointestinal microflora and mucins may play a critical role in the development of 5-fluorouracil-induced gastrointestinal mucositis. Exp. Biol. Med. 234, 430-441. doi: 10.3181/0810-RM-301
150. Stringer, A. M., Gibson, R. J., Logan, R. M., Bowen, J. M., Yeoh, A. S., Laurence, J., et al. (2009d). Irinotecan-induced mucositis is associated with changes in intestinal mucins. Cancer Chemother. Pharmacol. 64, 123-132. doi: 10.1007/s00280-008-0855-y
151. Stringer, A. M., Gibson, R. J., Logan, R. M., Bowen, J. M., Yeoh, A. S., Burns, J., et al. (2007). Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat. Exp. Biol. Med. 232, 96-106.
152. Stringer, A. M., Gibson, R. J., Logan, R. M., Bowen, J. M., Yeoh, A. S., and Keefe, D. M. (2008). Faecal microflora and β-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats. Cancer Biol. Ther. 7, 1919-1925. doi: 10.4161/cbt.7.12.6940
153. Suzuki, T., Sakai, H., Ikari, A., and Takeguchi, N. (2000). Inhibition of thromboxane A2-induced Cl-secretion by antidiarrhea drug loperamide in isolated rat colon. J. Pharmacol. Exp. Ther. 295, 233-238.
154. Tacar, O., Sriamornsak, P., and Dass, C. R. (2013). Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J. Pharm. Pharmacol. 65, 157-170. doi: 10.1111/j.2042-7158.2012.01567.x
155. Takasuna, K., Hagiwara, T., Hirohashi, M., Kato, M., Nomura, M., Nagai, E., et al. (1996). Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res. 56, 3752-3757.
156. Talley, N. J. (2003). Definitions, epidemiology, and impact of chronic constipation. Rev. Gastroenterol. Disord. 4, S3-S10.
157. Thiagarajah, J., Donowitz, M., and Verkman, A. (2015). Secretory diarrhoea: mechanisms and emerging therapies. Nat. Rev. Gastroenterol. Hepatol. 12, 446-457. doi: 10.1038/nrgastro.2015.111
158. Thiagarajah, J., and Verkman, A. (2012). CFTR inhibitors for treating diarrheal disease. Clin. Pharmacol. Ther. 92, 287-290. doi: 10.1016/j.cgh.2013.12.001
159. Thiagarajah, J., and Verkman, A. (2013). Chloride channel-targeted therapy for secretory diarrheas. Curr. Opin. Pharmacol. 13, 888-894. doi: 10.1016/j.coph.2013.08.005
160. Thomas, J., Karver, S., Cooney, G. A., Chamberlain, B. H., Watt, C. K., Slatkin, N. E., et al. (2008). Methylnaltrexone for opioid-induced constipation in advanced illness. N. Engl. J. Med. 358, 2332-2343. doi: 10.1056/NEJMoa0707377
161. Thomas, J., Lipman, A., Slatkin, N., Wilson, G., Moehl, M., Wellman, C., et al. (2005). A phase III double-blind placebo-controlled trial of methylnaltrexone (MNTX) for opioid-induced constipation (OIC) in advanced medical illness (AMI). Proc. Am. Soc. Clin. Oncol. 25:8003.
162. Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet-Tieulent, J., and Jemal, A. (2015). Global cancer statistics, 2012. CA Cancer J. Clin. 65, 87-108. doi: 10.3322/caac.21262
163. Touchefeu, Y., Montassier, E., Nieman, K., Gastinne, T., Potel, G., Bruley Des Varannes, S., et al. (2014). Systematic review: the role of the gut microbiota in chemotherapy-or radiation-induced gastrointestinal mucositis-current evidence and potential clinical applications. Aliment. Pharmacol. Ther. 40, 409-421.
164. Twycross, R., Sykes, N., Mihalyo, M., and Wilcock, A. (2012). Stimulant laxatives and opioid-induced constipation. J. Pain Symptom Manage. 43, 306-313. doi: 10.1016/j.jpainsymman.2011.12.002
165. Tzavella, K., Riepl, R. L., Klauser, A. G., Voderholzer, W. A., Schindlbeck, N. E., and Müller-Lissner, S. A. (1996). Decreased substance P levels in rectal biopsies from patients with slow transit constipation. Eur. J. Gastroenterol. Hepatol. 8, 1207-1211. doi: 10.1097/00042737-199612000-00014
166. van Vliet, M. J., Harmsen, H. J., De Bont, E. S., and Tissing, W. J. (2010). The role of intestinal microbiota in the development and severity of chemotherapy-induced mucositis. PLoS Pathogens 6:e1000879. doi: 10.1371/journal.ppat.1000879
167. Vera, G., Castillo, M., Cabezos, P., Chiarlone, A., Martín, M., Gori, A., et al. (2011). Enteric neuropathy evoked by repeated cisplatin in the rat. Neurogastroenterol. Motil. 23, 370-378. doi: 10.1111/j.1365-2982.2011.01674.x
168. Verstappen, C. C., Heimans, J. J., Hoekman, K., and Postma, T. J. (2003). Neurotoxic complications of chemotherapy in patients with cancer. Drugs 63, 1549-1563. doi: 10.2165/00003495-200363150-00003
169. Viele, C. S. (2003). Overview of chemotherapy-induced diarrhea. Semin. Oncol. Nurs. 19, 2-5. doi: 10.1053/j.soncn.2003.09.007
170. Wadler, S., Benson, A., Engelking, C., Catalano, R., Field, M., Kornblau, S. M., et al. (1998). Recommended guidelines for the treatment of chemotherapy-induced diarrhea. J. Clin. Oncol. 16, 3169-3178.
171. Wafai, L., Taher, M., Jovanovska, V., Bornstein, J. C., Dass, C. R., and Nurgali, K. (2013). Effects of oxaliplatin on mouse myenteric neurons and colonic motility. Front. Neurosci. 7:30. doi: 10.3389/fnins.2013.00030
172. Wagner, A. D., Grothe, W., Haerting, J., Kleber, G., Grothey, A., and Fleig, W. E. (2006). Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J. Clin. Oncol. 24, 2903-2909. doi: 10.1200/JCO.2005.05.0245
173. Walko, C. M., and Lindley, C. (2005). Capecitabine: a review. Clin. Ther. 27, 23-44. doi: 10.1016/j.clinthera.2005.01.005
174. Wallace, B. D., Roberts, A. B., Pollet, R. M., Ingle, J. D., Biernat, K. A., Pellock, S. J., et al. (2015). Structure and inhibition of microbiome β-glucuronidases essential to the alleviation of cancer drug toxicity. Chem. Biol. 22, 1238-1249. doi: 10.1016/j.chembiol.2015.08.005
175. Wallace, B. D., Wang, H., Lane, K. T., Scott, J. E., Orans, J., Koo, J. S., et al. (2010). Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 330, 831-835. doi: 10.1126/science.1191175
176. Webster, L., Jansen, J. P., Peppin, J., Lasko, B., Irving, G., Morlion, B., et al. (2008). Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain 137, 428-440. doi: 10.1016/j.pain.2007.11.008
177. Wolff, R. A., Evans, D. B., Gravel, D. M., Lenzi, R., Pisters, P. W., Lee, J. E., et al. (2001). Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin. Cancer Res 7, 2246-2253.
178. Wong, B. S., Camilleri, M., Busciglio, I., Carlson, P., Szarka, L. A., Burton, D., et al. (2011). Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome. Gastroenterology 141, 1638-1647. doi: 10.1053/j.gastro.2011.07.036
179. Wood, J. D., and Galligan, J. J. (2004). Function of opioids in the enteric nervous system. Neurogastroenterol. Motil. 16, 17-28. doi: 10.1111/j.1743-3150.2004.00554.x
180. Xing, J. H., and Soffer, E. E. (2001). Adverse effects of laxatives. Dis. Colon Rectum 44, 1201-1209. doi: 10.1007/BF02234645
181. Xue, H., Sawyer, M. B., Wischmeyer, P. E., and Baracos, V. E. (2011). Nutrition modulation of gastrointestinal toxicity related to cancer chemotherapy from preclinical findings to clinical strategy. J. Parenter. Enteral Nutr. 35, 74-90. doi: 10.1177/0148607110377338
182. Yamagishi, A., Morita, T., Miyashita, M., and Kimura, F. (2009). Symptom prevalence and longitudinal follow-up in cancer outpatients receiving chemotherapy. J. Pain Symptom Manage. 37, 823-830. doi: 10.1016/j.jpainsymman.2008.04.015
183. Yang, X., Hu, Z., Chan, S. Y., Chan, E., Goh, B. C., Duan, W., et al. (2005). Novel agents that potentially inhibit irinotecan-induced diarrhea. Curr. Med. Chem. 12, 1343-1358. doi: 10.2174/0929867054020972